Aska Hd Report

Overview

The report covers ASKA Pharmaceutical Holdings' first year after its establishment as a holding company, with consolidated net sales reaching 56,607 million yen. It describes a Group-wide ESG structure built around an ESG Committee and 17 material issues, including environmental, social, and governance priorities. The report also presents TCFD-aligned climate-risk and opportunity disclosures and a 46% CO2 reduction target from FY2013 by FY2030. Human-capital highlights include Group-wide health-check and stress-check targets of 100% and increased representation of women among officers.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2021
Period: 1 April 2021 – 31 March 2022
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services